Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
AEterna Zentaris's prostate drug disappoints in Phase III
18 August 2009
Asher Mullard

asher.mullard@informa.com

Two Phase III trials of AEterna Zentaris's lead drug candidate cetrorelix pamoate showed the drug is safe but not effective for the treatment of enlarged prostate. The company's share price plummeted by 60%, to close at $1.14 on Nasdaq on August 17th.

Cetrorelix pamoate is a sustained-release...



Please Login to read the full article.
 
Not a subscriber? Subscribe to Scrip Request a FREE Trial
RELATED CONTENT
NEWS Scrip News Other Informa News
COMMENT Scrip Comment Other Informa Comment
FEATURES Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK Promote your vacancy here
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm